Universiteit Leiden

nl en

Cluster Systems Pharmacology

The aim of the cluster Systems Pharmacology lies in the development of personalised medicine strategies, and development of new systems-based approaches in translational and clinical pharmacology.

Welcome to the Cluster of Systems Pharmacology, which combines the divisions Pharmacology (Dr. Liesbeth de Lange, Prof. Van der Graaf (extraordinary), Prof. Knibbe and Prof. Danhof) and Analytical Biosciences (Prof. Hankemeier, Prof. Van der Greef).

Previously, medical treatments and drugs were designed for an "average patient". This may provide success for some patients, but not for others. Today, the importance to step away from a one-size-fits-all" approach however, has become clear. And we aim for a much more effective approach that takes into account the differences between individuals, their genes, environments, lifestyles, all of which also influences their individual responses to treatment.

This calls for a thorough understanding of diseases, at the system-level, and aimed at predicting the modulation of disease networks by drugs in cells, organs, and the body as a whole. To achieve this, we gather metabolomics-data from patients and preclinical in-vitro models that are derived from patients. (organ-on-a-chip models using human iPSC derived cells) or in vivo data which we integrate into systems pharmacology modelling.

Our new strategies on pharmacology and personalised medicine development, require further clinical collaborations to help us optimizing and validating. In the end, to result in concepts of system therapeutics.


Research themes and Principal Investigators:

Highly sensitive analysis using 3D cell culture model

Contact: Thomas Hankemeier

A research goal for Analytical BioSciences is to develop miniaturized platforms for research in (stem)cell, in vitro systems and application in clinical and preventive research.

Read more >


Clinical applications of (pharmaco)metabolomics

Contact Thomas Hankemeier:

The prediction of the effect (efficiency and toxicity) of a drug in a patient is very important in (i) clinical decision support and (ii) the development of novel drug treatments.

Read more>


Development of Comprehensive and High-throughput metabolomics techniques

Contact: Dr. A. Mashaghi Tabari, Thomas Hankemeier,

A major goal of Analytical BioSciences research is to overcome one of the major bottle-necks in metabolomic research: the lack of a high-throughput infrastructure in which thousands of samples can be processed in a standardized and cost-effective way

Read more>


Translational Pharmacology

Contact: Liesbeth de Lange

The aim of this research area is to be able to predict human drug response on the basis of mathematical models that are developed using preclinical experiments and prior knowledge

Read more >


Clinical Pharmacology

Contact: Catherijne Knibbe

Knowledge on how to adjust a drug dose in special patient populations such as (prematurely born) neonates or children, critically-ill patients, obese individuals, or pregnant women, is not only crucial for novel compounds but also for existing drugs which are often used in an off-label manner.

Read more >


Quantitative Systems Pharmacology

Contact: Coen van Hasselt , Piet Hein van der Graaf,

This research area is focused on the development and application of novel concepts and models in the emerging area of quantitative systems pharmacology (QSP).

Read more>